)
The first placebo-controlled, double-blind study evaluating edaravone for efficacy and safety, conducted over a 36 week period (with a 12 week pre-treatment observational period), was not able to demonstrate that edaravone was efficacious for ALS \cite{Abe_2014}. However, during the 24 weeks of intervention (edaravone compared to placibo), there was a decrease in progressive decline in ALS based on the ALSFRS-R in the patients receiving edaravone (−5.70 ± 0.85, n=102) compared to those receiving the placebo ( −6.35 ± 0.84, n=104), while the adverse events were similar between the edaravone and placebo groups. The second phase-3 trial